CPT-Pharmacometrics & Systems Pharmacology
Scope & Guideline
Advancing drug discovery through innovative modeling.
Introduction
Aims and Scopes
- Population Pharmacokinetics and Pharmacodynamics:
The journal publishes studies that develop and apply population PK/PD models to optimize drug dosing regimens and evaluate drug efficacy and safety across diverse patient populations. - Physiologically-Based Pharmacokinetic Modeling:
There is a strong emphasis on physiologically-based pharmacokinetic (PBPK) modeling, which allows for the prediction of drug absorption, distribution, metabolism, and excretion based on physiological and biochemical parameters. - Model-Informed Drug Development:
The articles frequently discuss model-informed drug development strategies, highlighting how quantitative models can inform clinical trial designs and dosing decisions. - Systems Pharmacology Approaches:
The integration of systems pharmacology into pharmacometric analyses is a key focus, addressing complex biological interactions and the dynamics of drug effects at the systems level. - Innovative Methodologies:
The journal features innovative methodologies, including machine learning and Bayesian approaches, to enhance pharmacometric analyses and improve predictive accuracy. - Clinical Application and Regulatory Perspectives:
Research published in the journal often includes clinical applications of pharmacometric models, providing insights into regulatory considerations and real-world implications for drug therapies.
Trending and Emerging
- Model-Informed Precision Dosing:
There is a growing emphasis on model-informed precision dosing, which tailors drug dosages based on individual patient characteristics and pharmacokinetic profiles, enhancing therapeutic efficacy and safety. - Integration of Machine Learning:
The application of machine learning techniques in pharmacometrics is on the rise, facilitating the development of predictive models and improving the efficiency of data analysis in drug development. - Pediatric Pharmacokinetics:
Research focusing on pediatric populations, including the development of age-specific pharmacokinetic models, is increasingly prominent, addressing the unique physiological characteristics of children. - Real-World Data Utilization:
The use of real-world data in pharmacometric modeling to inform clinical decision-making and regulatory submissions is becoming more prevalent, reflecting a shift towards more applicable and relevant research. - Systems Pharmacology in Oncology:
Emerging studies are increasingly utilizing systems pharmacology approaches to model complex interactions in cancer therapies, including immunotherapies and combination treatments, to better understand treatment outcomes. - Drug-Drug Interaction Modeling:
There is a heightened focus on modeling drug-drug interactions, particularly using PBPK approaches, to predict safety and efficacy in patients receiving multiple therapies.
Declining or Waning
- Traditional Compartmental Modeling:
While traditional compartmental models have been foundational in pharmacokinetics, there is a noticeable reduction in studies solely relying on these methods without integrating more complex systems or physiologically-based approaches. - Single-Agent Pharmacokinetics:
Research focusing exclusively on the pharmacokinetics of single-agent therapies is becoming less common, as there is a shift towards combination therapies and multi-drug regimens. - Non-Quantitative Studies:
There is a decline in the publication of non-quantitative studies or those lacking robust statistical analysis, as the journal increasingly prioritizes articles with rigorous quantitative methods. - Basic Pharmacokinetic Studies:
Basic studies that do not incorporate advanced modeling techniques or system-level insights are less frequently published, signaling a move towards more integrative and complex analyses.
Similar Journals
International Journal of Pharmacology
Connecting Laboratory Discoveries to Clinical PracticeWelcome to the International Journal of Pharmacology, a key publication in the field of pharmacology, published by ASIAN NETWORK SCIENTIFIC INFORMATION (ANSINET). Since its inception in 2006, this journal has provided a vital platform for researchers and professionals to disseminate their findings and insights in pharmacology, toxicology, and pharmaceutics. Despite recent discontinuation in Scopus coverage, the journal's dedication to fostering scientific dialogue continues to attract contributions from esteemed scholars globally. With an **ISSN of 1811-7775** and **E-ISSN of 1812-5700**, the journal seeks to bridge the gap between laboratory research and clinical application, promoting a deeper understanding of drug actions and interactions. Although it operates under traditional access options, the relevance of its published studies to ongoing pharmacological research remains significant.
BIOPHARMACEUTICS & DRUG DISPOSITION
Empowering Discoveries in BiopharmaceuticsBIOPHARMACEUTICS & DRUG DISPOSITION, published by WILEY, is a prominent journal in the fields of biopharmaceutics and pharmacology, dedicated to the dissemination of vital research that spans from the foundational aspects of drug disposition to advanced therapeutic developments. Since its inception in 1979, this journal has established itself as a crucial resource for a diverse audience, including researchers, professionals, and students. With its impact factor indicating solid performance and a current ranking in Q2 for Pharmaceutical Science and Q3 across miscellaneous medicine categories, BIOPHARMACEUTICS & DRUG DISPOSITION serves as a nexus for innovative studies and breakthrough findings. The journal's comprehensive scope ensures that rigorous scientific inquiry is represented, helping to advance the understanding of drug behavior in biological systems. Participating in this scholarly dialogue not only enhances individual knowledge but contributes to the broader pharmaceutical and medical communities, making it an essential publication for all stakeholders interested in drug development and utilization.
DARU-Journal of Pharmaceutical Sciences
Elevating the discourse in drug discovery and pharmacology.DARU-Journal of Pharmaceutical Sciences is a leading peer-reviewed journal published by SPRINGER INT PUBL AG that focuses on the dynamic and rapidly evolving fields of pharmaceutical sciences, including drug discovery, pharmacology, and toxicology. With an impressive Q2 ranking in both Drug Discovery and Miscellaneous Medicine categories for 2023, this journal stands out as a vital resource for researchers, professionals, and students alike, offering a platform for significant contributions to the scientific community. Covering a comprehensive scope from 2000 to 2024 and indexed by Scopus, the journal ranks within the top percentile in its field, with a ranking of #66/313 in Pharmacology and #34/157 in Drug Discovery, reaffirming its impact and relevance. The journal promotes open access to foster widespread dissemination of knowledge in pharmaceutical sciences, ultimately aiming to bridge the gap between research and clinical applications. For those looking to stay at the forefront of pharmaceutical innovation, DARU represents an invaluable connection to the latest studies and breakthrough findings.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
Fostering Collaboration in Pharmacological StudiesJOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, published by Springer/Plenum Publishers, stands as a vital resource in the field of pharmacology. With an ISSN of 1567-567X and an E-ISSN of 1573-8744, this journal is well-regarded within the academic community, as reflected in its Q2 ranking in the 2023 Scopus category for Pharmacology. Spanning years from 1996 to 2024, it serves as a comprehensive platform for cutting-edge research on the interactions of drugs within the body, their effects, and the underlying pharmacological mechanisms. The journal provides a critical avenue for dissemination of significant research findings, with a focus on enhancing understanding in pharmacokinetics, pharmacodynamics, and their implications in therapeutic practices. Targeting an audience of researchers, professionals, and students, the journal emphasizes high-quality manuscripts that contribute to the advancement of knowledge in pharmacology. Although currently not an open access journal, it maintains a strong commitment to promoting scientific communication and collaboration.
BMC Pharmacology & Toxicology
Fostering collaboration in pharmacology and toxicology.Welcome to BMC Pharmacology & Toxicology, a premier open-access journal dedicated to advancing the fields of pharmacology and toxicology. Published by BMC since 2012, this esteemed journal offers a platform for researchers, professionals, and students to disseminate cutting-edge research and innovative findings that explore the intricate interactions between drugs and biological systems. With its robust Q2 ranking in both general medicine and pharmacology categories for 2023, BMC Pharmacology & Toxicology is recognized for its significant contributions to the academic community, reflected in its strategic positioning within the 61st and 49th percentiles in Scopus rankings for related disciplines. The journal's commitment to open access ensures that vital research is accessible to a global audience, fostering collaboration and informed discussions. We invite you to engage with the latest studies, reviews, and innovative methodologies that shape the future of pharmacological and toxicological sciences.
Journal of Biopharmaceutical Statistics
Elevating standards in statistical methodologies for drug discovery.Journal of Biopharmaceutical Statistics, published by Taylor & Francis Inc, is a premier scholarly journal that has been contributing to the fields of biostatistics and pharmacology since its inception in 1991. With an impressive track record spanning over three decades, it holds a significant place in the academic landscape, particularly evidenced by its Q2 quartile rankings in Pharmacology, Pharmacology (Medical), and Statistics and Probability as of 2023. The journal serves as a vital platform for researchers, professionals, and students, disseminating critical statistical methodologies and innovative analyses that enhance drug development and biopharmaceutical research. Although not open access, it provides invaluable insights through meticulously peer-reviewed articles that tackle pressing issues in pharmacometric modeling, clinical trial design, and statistical theory. As the biopharmaceutical industry evolves, Journal of Biopharmaceutical Statistics remains pivotal in fostering scientific discovery and excellence.
Clinical Pharmacology in Drug Development
Exploring the future of drug efficacy and safety.Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.
JOURNAL OF CLINICAL PHARMACOLOGY
Innovating Insights in Clinical PharmacologyWelcome to the Journal of Clinical Pharmacology, an esteemed publication in the field of pharmacology and medical pharmacology, published by Wiley. Since its inception in 1973, this journal has been at the forefront of disseminating innovative research findings and comprehensive reviews that enhance our understanding of drug therapies and their clinical applications. With an impact factor that reflects its strong reputation and a Scopus ranking placing it in the 64th percentile among 272 journals in medical pharmacology, the journal stands as a critical resource for researchers, healthcare professionals, and students alike. Although currently not an Open Access journal, it provides invaluable insights into therapeutic drug use and safety, the pharmacokinetics of drugs, and the development of new therapeutic strategies. The journal's commitment to advancing the field through high-quality, peer-reviewed articles ensures it remains a vital asset in the continuously evolving landscape of clinical pharmacology.
DRUG DEVELOPMENT RESEARCH
Pioneering insights in pharmacology and toxicology.DRUG DEVELOPMENT RESEARCH is a premier interdisciplinary journal published by Wiley, focusing on the latest advancements in drug discovery, pharmacology, and toxicology. With an ISSN of 0272-4391 and an E-ISSN of 1098-2299, this esteemed publication has been a cornerstone in the field since its inception in 1981 and continues to provide cutting-edge research until 2024. Its rigorous peer-review process and strategic placement in Q2 of the Drug Discovery category, as well as ranking #60 out of 157 in Scopus, underscore the journal's relevance and influence, boasting a respectable 62nd percentile ranking. While the journal does not currently offer open access, it remains a vital resource for researchers, professionals, and students seeking to expand their knowledge on the processes of drug development, identifying new therapeutic targets, and assessing the efficacy and safety of novel compounds. Situated in Hoboken, NJ, this journal stands at the forefront of pharmaceutical innovation, making significant contributions to the advancement of medical science.
DRUGS IN R&D
Unlocking the potential of pharmacological sciences globally.DRUGS IN R&D is a premier open access journal dedicated to advancing the field of pharmacology and drug development. Published by Springer International Publishing AG, this journal has been a valuable resource for researchers and professionals since its inception in 1999, contributing critical insights into the pharmacological sciences. With an impressive Impact Factor reflecting its significance, DRUGS IN R&D ranks in the Q2 quartile for Pharmacology, according to 2023 metrics, and ranks #151 out of 313 in the field of pharmacology and toxicology on Scopus. This journal offers an open access format, ensuring high visibility and accessibility of research findings to a global audience, supporting the intrepid pursuit of knowledge in drug research and development. By facilitating comprehensive discussions and innovative research findings, DRUGS IN R&D plays a crucial role in shaping the future landscape of pharmacological studies and advancements.